

Eugenio Borsatti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1751461/publications.pdf>

Version: 2024-02-01

42
papers

1,180
citations

623734

14
h-index

434195

31
g-index

44
all docs

44
docs citations

44
times ranked

1688
citing authors

#	ARTICLE	IF	CITATIONS
1	Sequencing Life-Prolonging Agents in Castration-Resistant Prostate Cancer Patients: Comparison of Sequences With and Without 223Ra. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2021, 36, 391-396.	1.0	2
2	10-Year Clinical Experience With 18F-Choline PET/CT. <i>Clinical Nuclear Medicine</i> , 2020, 45, 594-603.	1.3	6
3	PO-063 Induction chemotherapy followed by radiotherapy for organ preservation in Oropharyngeal Cancer. <i>Radiotherapy and Oncology</i> , 2019, 132, 33-34.	0.6	0
4	PO-122 CT /PET based dosiomics and radiomics model predicts local control of nasopharyngeal carcinoma. <i>Radiotherapy and Oncology</i> , 2019, 132, 62-63.	0.6	0
5	PO-164 Regional nodal failure after primary treatment for differentiated thyroid cancer. <i>Radiotherapy and Oncology</i> , 2019, 132, 87.	0.6	0
6	EP-1143 Regional nodal failure after primary treatment for differentiated thyroid cancer.. <i>Radiotherapy and Oncology</i> , 2019, 133, S634-S635.	0.6	0
7	FDG PET in response evaluation of bulky masses in paediatric Hodgkin's lymphoma (HL) patients enrolled in the Italian AIEOP-LH2004 trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 97-106.	6.4	9
8	Results From a Large, Multicenter, Retrospective Analysis On Radium223 Use in Metastatic Castration-resistant Prostate Cancer (mCRPC) in the Triveneto Italian Region. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e187-e194.	1.9	14
9	Italian Multicenter Study on Accuracy of 18 F-FDG PET/CT in Assessing Bone Marrow Involvement in Pediatric Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e267-e273.	0.4	15
10	Ectopic Adrenocorticotrophic Hormone-“Secreting Pituitary Adenoma Localized by 18F-Choline PET/CT. <i>Clinical Nuclear Medicine</i> , 2018, 43, e25-e26.	1.3	12
11	Re: 18F-Fluorocholine PET/CT of Incidental Male Breast Cancer. <i>Clinical Nuclear Medicine</i> , 2018, 43, 75-76.	1.3	1
12	Unusual presentation of recurrent papillary thyroid microcarcinoma with neck muscles and skin dissemination. <i>Hormones</i> , 2018, 17, 589-591.	1.9	1
13	Preoperative Radiation Therapy with a Simultaneous Integrated Boost Compared to Chemoradiotherapy for cT3-4 Rectal Cancer: A Multicentric Randomized Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, S64.	0.8	0
14	²²³ Ra-chloride therapy in men with hormone-refractory prostate cancer and skeletal metastases: Real-world experience. <i>Tumori</i> , 2018, 104, 128-136.	1.1	14
15	Sequencing radium 223 (RA223) for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) in the daily practice: Preliminary results from a retrospective study in Italian centers.. <i>Journal of Clinical Oncology</i> , 2018, 36, 322-322.	1.6	1
16	Patient (pt) characteristics and treatment patterns in the radium (Ra)-223 REASSURE observational study. <i>Annals of Oncology</i> , 2017, 28, vi22-vi23.	1.2	0
17	Malignant struma ovarii harboring a unique NRAS mutation: case report and review of the literature. <i>Hormones</i> , 2017, 16, 322-327.	1.9	11
18	223Ra-chloride therapy: the first multidisciplinary and multicenter Italian study. <i>Annals of Oncology</i> , 2017, 28, vi23.	1.2	0

#	ARTICLE	IF	CITATIONS
19	Malignant struma ovarii harboring a unique NRAS mutation: case report and review of the literature. <i>Hormones</i> , 2017, 13, 322-327.	1.9	9
20	Approaches for Assessment of Response of Bone Metastases to Therapies. , 2017, , 223-249.		0
21	Decompressive percutaneous endoscopic gastrostomy in advanced cancer patients with small-bowel obstruction is feasible and effective: a large prospective study. <i>Supportive Care in Cancer</i> , 2016, 24, 2877-82.	2.2	27
22	OC-0145: Preoperative radiotherapy with an integrated boost compared to chemoradiotherapy for rectal cancer. <i>Radiotherapy and Oncology</i> , 2016, 119, S66.	0.6	1
23	First Italian Multicentre Experience in using Ra-223 in patients with metastatic castration resistant prostate cancer (mCRPC). <i>Annals of Oncology</i> , 2016, 27, iv35.	1.2	0
24	Interim Positron Emission Tomography Responseâ€“Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 1376-1385.	1.6	128
25	Gleason Score at Diagnosis Predicts the Rate of Detection of ¹⁸ F-Choline PET/CT Performed When Biochemical Evidence Indicates Recurrence of Prostate Cancer: Experience with 1,000 Patients. <i>Journal of Nuclear Medicine</i> , 2015, 56, 209-215.	5.0	69
26	The ability of 18F-choline PET/CT to identify local recurrence of prostate cancer. <i>Abdominal Imaging</i> , 2015, 40, 3230-3237.	2.0	27
27	Concurrent chemoradiotherapy with tomotherapy in locally advanced non-small cell lung cancer: a phase I, docetaxel dose-escalation study, with hypofractionated radiation regimen. <i>BMC Cancer</i> , 2013, 13, 513.	2.6	16
28	Incidental Detection of Leydig Cell Tumor Via Fluorine-18-Choline PET/CT in a Patient With Recurrent Prostate Cancer Disease. <i>Clinical Nuclear Medicine</i> , 2013, 38, 752-754.	1.3	6
29	Oxaliplatin and Capecitabine (XELOX) Based Chemotherapy in the Treatment of Metastatic Colorectal Cancer: The Right Choice in Elderly Patients. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2013, 13, 1344-1353.	1.7	10
30	<i>In vivo</i> dosimetry with radiochromic films in low-voltage intraoperative radiotherapy of the breast. <i>Medical Physics</i> , 2012, 39, 2359-2368.	3.0	50
31	Revisiting the Clinical Value of 18F-FDG PET/CT in Detection of Recurrent Epithelial Ovarian Carcinomas. <i>Clinical Nuclear Medicine</i> , 2012, 37, e184-e188.	1.3	50
32	MMP-13 stimulates osteoclast differentiation and activation in tumour breast bone metastases. <i>Breast Cancer Research</i> , 2011, 13, R105.	5.0	92
33	Treatment of recurrent high-grade gliomas with GliSite brachytherapy: a prospective mono-institutional Italian experience. <i>Tumori</i> , 2011, 97, 614-9.	1.1	9
34	Pitfalls in the dermoscopic diagnosis of amelanotic melanoma. <i>Journal of the American Academy of Dermatology</i> , 2010, 62, 893-894.	1.2	11
35	Detection and Restaging of Residual and/or Recurrent Nasopharyngeal Carcinoma after Chemotherapy and Radiation Therapy: Comparison of MR Imaging and FDG PET/CT. <i>Radiology</i> , 2008, 249, 203-211.	7.3	111
36	[18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006, 33, 1387-1398.	6.4	304

#	ARTICLE	IF	CITATIONS
37	Somatostatin receptor scintigraphy versus chromogranin A assay in the management of patients with neuroendocrine tumors of different types: clinical role. <i>Annals of Oncology</i> , 2003, 14, 1135-1141.	1.2	67
38	Pharmacokinetics of vinorelbine in patients with liver metastases. <i>Clinical Pharmacology and Therapeutics</i> , 1996, 59, 32-40.	4.7	72
39	The use of thallium-201 in the preoperative detection of breast cancer: an adjunct to mammography and ultrasonography. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1995, 22, 1110-1117.	2.1	27
40	Quantitative liver function by monoethylglycinexylidide (MEGX) test in liver metastases. <i>Gastroenterology</i> , 1995, 108, A454.	1.3	2
41	Correlation between the quantitative liver function test "MEGX" and vinorelbine clearance in patients with breast cancer. <i>Gastroenterology</i> , 1995, 108, A1044.	1.3	0
42	Usefulness of immunoscintigraphy in the follow-up of surgically treated gastrointestinal carcinomas using 111In-labelled anti-CEA monoclonal antibodies. <i>Clinical Oncology</i> , 1992, 4, 368-372.	1.4	0